Drug-eluting Balloons

Drug-eluting balloons (DEB) are conventional semi-compliant angioplasty balloons covered with an anti-proliferative drug which is released into the vessel wall during inflation of the balloon, usually at nominal pressures with a specific minimal inflation time. The active substance on the DEB should be lipophilic enough to have a high absorption rate through tht vessel wall to compensate for the short period of contact between the inflated balloon and the vessel wall itself, and to maintain a sustained effect once released.

DEBs are typically used in re-stenotic lesions - previously stented segments that have developed neointimal hyperplasia and luminal loss. The advantage of this approach over the use of DES include a more homogeneous drug distribution and the fact that this mode of local delivery does not require foreign material implantation. Moreover, the recently introduced concept of “combined treatment strategy” of bare metal stent followed by DEB has aroused interest within interventional cardiology.

Although different DEBs appear similar in the underlying concept, the technical differences are important and include different coating techniques and applications of the different products in the market. As new information emerges over their potential indications and usage, there is a great deal to learn about DEBs.

Videos

Drug-eluting balloons (DEB) are conventional semi-compliant angioplasty balloons covered with an anti-proliferative drug which is released into the vessel wall during inflation of the balloon, usually at nominal pressures with a specific minimal inflation time. The active substance on the DEB should be lipophilic enough to have a high absorption rate through tht vessel wall to compensate for the short period of contact between the inflated balloon and the vessel wall itself, and to maintain a sustained effect once released.

DEBs are typically used in re-stenotic lesions - previously stented segments that have developed neointimal hyperplasia and luminal loss. The advantage of this approach over the use of DES include a more homogeneous drug distribution and the fact that this mode of local delivery does not require foreign material implantation. Moreover, the recently introduced concept of “combined treatment strategy” of bare metal stent followed by DEB has aroused interest within interventional cardiology.

Although different DEBs appear similar in the underlying concept, the technical differences are important and include different coating techniques and applications of the different products in the market. As new information emerges over their potential indications and usage, there is a great deal to learn about DEBs.

Arterial & Venous Endovascular Conference (CVC) & Simple Education Partnership

The CVC / Simple Partnership:

In July 2016, Simple Education and CVC entered into a unique partnership where ALL CVC content is hosted on the platform, we are pleased to introduce you to this world class content and this innovative medical education platform that is truly a leap forwards in how medical education is delivered.

CVC 2016:

CVC is a winning formula of world renowned faculty, dedicated attendees and ground-breaking content in an immersive and focused atmosphere.

Balloon- or Self-Expandable TAVI: Clinical Equipoise?

Transcatheter aortic valve implantation (TAVI) has undergone tremendous technological advancements since the first successful implantation in 2002 for symptomatic severe aortic valve stenosis (AS).1 It is currently considered as the standard of care for severe AS patients who have high surgical risk or may be deemed unsuitable for surgery.2 Broadly, there are two main categories of transcatheter aortic valve prostheses: balloon-expandable (BE) and self-expandable (SE).

Cardionovum® begins clinical study of APERTO® Drug Coated Balloon (DCB), designed for long-term prevention of shunt restenosis in hemodialysis patients

Cardionovum® begins clinical study of APERTO® Drug Coated Balloon (DCB), designed for long-term prevention of shunt restenosis in hemodialysis patients

CEO Dr. Michael Orlowski is considered the pioneer of Drug Coated Balloons, having invented the first CE-marked DCB for the cardiovascular market in 2007 

Bioresorbable Scaffolds

Percutaneous coronary intervention (PCI) is one of the most commonly performed procedures in cardiology. More recently, the limitations of rigid metallic stents have led to the development of bioresorbable scaffolds (BRS). The earliest version of bioresorbable stent developed and tested in humans in 1990 was the Igaki-Tamai stent. It featured a thermal and balloon expandable stent that showed good outcomes at six months1 as well as long-term2 with neointimal hyperplasia similar to bare metal stents (BMS).